Lux Biosciences Names Dean Mitchell President and CEO

Lux Biosciences Names Dean Mitchell President and CEO

JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc. today announced the appointment of Dean Mitchell, formerly President and Chief Executive Officer of Alpharma, as President and CEO.

"Dean Mitchell brings to Lux Biosciences an outstanding track record of success in building companies and growing value at both specialty pharmaceutical companies and large global firms such as Bristol-Myers Squibb and GlaxoSmithKline," said David Guyer, M.D., Chairman of the Lux Biosciences board of directors and Partner at SV Life Sciences. "We welcome him to the Lux Biosciences' team and look forward to seeing the company progress under his leadership towards the U.S. and European approval and eventual commercialization of Lux's first-in-class product for noninfectious uveitis, LuveniqTM (oral voclosporin)."

"As an oral therapy specifically developed for noninfectious uveitis, I am enthusiastic about Luveniq's potential to help patients with this difficult-to-treat inflammatory eye disease that is an important cause of blindness," said Mr. Mitchell. "With Lux Biosciences' innovative portfolio of products and delivery technologies, there are multiple strategic alternatives for developing the company, and I look forward to exploring these over the coming months."

Dean Mitchell Biography

Dean Mitchell is the former President, Chief Executive Officer and Director of Alpharma Inc., a public human and animal specialty pharmaceutical company, which was acquired by King Pharmaceuticals in December 2008. Prior to Alpharma, Mr. Mitchell was President and CEO of Guilford Pharmaceuticals, a publicly traded specialty pharmaceutical company that was acquired by MGI Pharmaceuticals in 2005. Before Guilford, Mr. Mitchell was at Bristol-Myers Squibb, where he was President, International and President, US Primary Care. Prior to BMS, Mr. Mitchell spent 14 years at GlaxoSmithKline, most recently as Senior Vice President, Clinical Development and Product Strategy. Mr. Mitchell earned his B.Sc. in Applied Biology from Coventry University in the United Kingdom and his M.B.A. from City University Business School, London, UK. He is also a non-executive Board member of ISTA Pharmaceutics, Intrexon and Talecris Biotherapeutics.

About Lux Biosciences

Lux Biosciences, Inc. is a privately held biotechnology company focused on the treatment of ophthalmic diseases. Lux Biosciences has exclusive worldwide rights to voclosporin for all ophthalmic indications and is cooperating with the team at Isotechnika Pharma who discovered the molecule. For more information on Lux Biosciences, please visit the company's website at